Interrupting the Mechanisms of Brain Injury in a Model of Maple Syrup Urine Disease Encephalopathy

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2011 May 5

PMID 21541722

Citations 9

Authors

William J Zinnanti

Jelena Lazovic

Affiliations

Soon will be listed here.

Abstract

Maple syrup urine disease (MSUD) was first recognized as an inherited lethal encephalopathy beginning in the first week of life and associated with an unusual odor in the urine of affected children. It was later confirmed as a deficiency of branched-chain keto acid dehydrogenase (BCKDH), which is the second step in branched-chain amino acid (BCAA) breakdown. MSUD is characterized by BCAA and branched-chain keto acid (BCKA) accumulation. BCAAs are essential amino acids and powerful metabolic signals with severe consequences of both deprivation and accumulation. Treatment requires life-long dietary restriction and monitoring of BCAAs. However, despite excellent compliance, children commonly suffer metabolic decompensation during intercurrent illness resulting in life-threatening cerebral edema and dysmyelination. The mechanisms underlying brain injury have been poorly understood. Recent studies using newly developed mouse models of both classic and intermediate MSUD have yielded insight into the consequences of rapid BCAA accumulation. Additionally, these models have been used to test preliminary treatments aimed at competing with blood-brain barrier transport of BCAA using norleucine. Assessment of biochemical changes with and without treatment suggests different roles for BCAA and BCKA in the mechanism of brain injury.

Citing Articles

Seizure Characteristics and EEG Features in Intoxication Type and Energy Deficiency Neurometabolic Disorders in the Pediatric Intensive Care Unit: Single-Center Experience Over 10 Years.

Sen K, Harrar D, Pariseau N, Tucker K, Keenan J, Zhang A Neurocrit Care. 2024; .

PMID: 39138714 DOI: 10.1007/s12028-024-02073-4.

Diet-induced dysbiosis of the maternal gut microbiome in early life programming of neurodevelopmental disorders.

Di Gesu C, Matz L, Buffington S Neurosci Res. 2021; 168:3-19.

PMID: 33992660 PMC: 9158738. DOI: 10.1016/j.neures.2021.05.003.

Dietary intake of branched-chain amino acids in a mouse model of Alzheimer's disease: Effects on survival, behavior, and neuropathology.

Tournissac M, Vandal M, Tremblay C, Bourassa P, Vancassel S, Emond V Alzheimers Dement (N Y). 2018; 4:677-687.

PMID: 30560200 PMC: 6290124. DOI: 10.1016/j.trci.2018.10.005.

Maple syrup urine disease: mechanisms and management.

Blackburn P, Gass J, Pinto E Vairo F, Farnham K, Atwal H, Macklin S Appl Clin Genet. 2017; 10:57-66.

PMID: 28919799 PMC: 5593394. DOI: 10.2147/TACG.S125962.

Neurocognitive profiles in MSUD school-age patients.

Bouchereau J, Leduc-Leballeur J, Pichard S, Imbard A, Benoist J, Abi Warde M J Inherit Metab Dis. 2017; 40(3):377-383.

PMID: 28324240 DOI: 10.1007/s10545-017-0033-7.

References

Schonberger S, Schweiger B, Schwahn B, Schwarz M, Wendel U . Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab. 2004; 82(1):69-75. DOI: 10.1016/j.ymgme.2004.01.016. View

Chuang D, Ku L, Cox R . Biochemical basis of thiamin-responsive maple syrup urine disease. Trans Assoc Am Physicians. 1982; 95:196-204. View

McKean C, BOGGS D, Peterson N . The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain. J Neurochem. 1968; 15(3):235-41. DOI: 10.1111/j.1471-4159.1968.tb06202.x. View

Donnell G, Lieberman E, SHAW K, Koch R . Hypoglycemia in maple syrup urine disease. Am J Dis Child. 1967; 113(1):60-3. DOI: 10.1001/archpedi.1967.02090160110012. View

TEWS J, REPA J, HARPER A . Branched-chain and other amino acids in tissues of rats fed leucine-limiting amino acid diets containing norleucine. J Nutr. 1991; 121(3):364-78. DOI: 10.1093/jn/121.3.364. View

Reed L . A trail of research from lipoic acid to alpha-keto acid dehydrogenase complexes. J Biol Chem. 2001; 276(42):38329-36. DOI: 10.1074/jbc.R100026200. View

MENKES J . Maple syrup disease and other disorders of keto acid metabolism. Res Publ Assoc Res Nerv Ment Dis. 1962; 40:69-93. View

Lieth E, LaNoue K, Berkich D, Xu B, Ratz M, Taylor C . Nitrogen shuttling between neurons and glial cells during glutamate synthesis. J Neurochem. 2001; 76(6):1712-23. DOI: 10.1046/j.1471-4159.2001.00156.x. View

Kimball S, Jefferson L . Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J Nutr. 2005; 136(1 Suppl):227S-31S. DOI: 10.1093/jn/136.1.227S. View

10.

Nyhan W, Klein J, Barshop B . Treatment of the acute crisis in maple syrup urine disease. Arch Pediatr Adolesc Med. 1998; 152(6):593-8. DOI: 10.1001/archpedi.152.6.593. View

11.

Harper P, Healy P, Dennis J . Maple syrup urine disease (branched chain ketoaciduria). Am J Pathol. 1990; 136(6):1445-7. PMC: 1877572. View

12.

Cremer J . Substrate utilization and brain development. J Cereb Blood Flow Metab. 1982; 2(4):394-407. DOI: 10.1038/jcbfm.1982.45. View

13.

She P, Reid T, Bronson S, Vary T, Hajnal A, Lynch C . Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab. 2007; 6(3):181-94. PMC: 2693888. DOI: 10.1016/j.cmet.2007.08.003. View

14.

MENKES J . Maple syrup disease; isolation and identification of organic acids in the urine. Pediatrics. 1959; 23(2):348-53. View

15.

Homanics G, Skvorak K, Ferguson C, Watkins S, Paul H . Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet. 2006; 7:33. PMC: 1448208. DOI: 10.1186/1471-2350-7-33. View

16.

Zinnanti W, Lazovic J, Griffin K, Skvorak K, Paul H, Homanics G . Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain. 2009; 132(Pt 4):903-18. PMC: 2668944. DOI: 10.1093/brain/awp024. View

17.

Strauss K, Mazariegos G, Sindhi R, Squires R, Finegold D, Vockley G . Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant. 2006; 6(3):557-64. DOI: 10.1111/j.1600-6143.2005.01209.x. View

18.

Kamei A, Takashima S, Chan F, Becker L . Abnormal dendritic development in maple syrup urine disease. Pediatr Neurol. 1992; 8(2):145-7. DOI: 10.1016/0887-8994(92)90038-z. View

19.

Dodd P, Williams S, Gundlach A, Harper P, Healy P, Dennis J . Glutamate and gamma-aminobutyric acid neurotransmitter systems in the acute phase of maple syrup urine disease and citrullinemia encephalopathies in newborn calves. J Neurochem. 1992; 59(2):582-90. DOI: 10.1111/j.1471-4159.1992.tb09409.x. View

20.

Islam M, Wallin R, Wynn R, Conway M, Fujii H, Mobley J . A novel branched-chain amino acid metabolon. Protein-protein interactions in a supramolecular complex. J Biol Chem. 2007; 282(16):11893-903. DOI: 10.1074/jbc.M700198200. View